BACKGROUND: Adding adjuvants such as MF59® to influenza vaccines can enhance the
immune response. This analysis evaluated the safety profile of MF59-adjuvanted [(+) MF59] …

We reviewed the safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in
children and adolescents (aged 6 months–18 years) in an integrated analysis of all pediatric …

Importance of the field: Vaccination is universally considered as the most effective tool for
the prevention of influenza, which represents a significant burden, both from a health-care …

Background: MF59-adjuvanted influenza vaccines have superior immunogenicity in older
adults compared with non-adjuvanted vaccines. We assessed whether changing formulation …

Objectives MF59-adjuvanted standard-dose and nonadjuvanted high-dose seasonal
influenza vaccines have been developed to protect the elderly at high risk of severe …

Background The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first
pandemic of the 21st century. Development of effective vaccines is a public health priority …

Background Standard‐dose seasonal influenza vaccines often produce modest
immunogenic responses in adults≥ 65 years old. MF59 is intended to elicit a greater …

Aim Adjuvanted influenza vaccines can overcome the poor antibody response of
conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity …

MF59-adjuvanted seasonal trivalent inactivated (ATIV) vaccine licensed since 1997 and
MF59-adjuvanted pandemic H1N1 vaccines have been distributed to approximately 80M …

MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for
more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad® …